Non-Hodgkin's lymphomas
Showing 1 - 25 of >10,000
Advanced Solid Tumors, B-cell Non-Hodgkin Lymphomas Trial (ATG-031)
Not yet recruiting
- Advanced Solid Tumors
- B-cell Non-Hodgkin Lymphomas
- (no location specified)
Aug 31, 2023
Relapsed or Refractory Non-Hodgkin's Lymphoma Trial in China (AXT-1003)
Not yet recruiting
- Relapsed or Refractory Non-Hodgkin's Lymphoma
-
Beijing, China
- +3 more
Jul 20, 2023
Relapsed/Refractory Non-Hodgkin Lymphoma Trial in Duarte, Amsterdam (BMS-986458, Rituximab)
Not yet recruiting
- Relapsed/Refractory Non-Hodgkin Lymphoma
-
Duarte, California
- +1 more
Oct 13, 2023
Non Hodgkin Lymphoma Trial in Cleveland (UF-KURE19 CAR-T cells, Fludarabine, Cyclophosphamide)
Recruiting
- Non Hodgkin Lymphoma
- UF-KURE19 CAR-T cells
- +2 more
-
Cleveland, Ohio
- +1 more
Nov 21, 2022
Non-Hodgkin Lymphoma, Hodgkin Lymphoma Trial in Minneapolis (drug, procedure, biological, radiation)
Recruiting
- Non-Hodgkin Lymphoma
- Hodgkin Lymphoma
- Etoposide
- +7 more
-
Minneapolis, MinnesotaMasonic Cancer Center, University of Minnesota
Jan 25, 2023
Relapsed/Refractory Indolent B Cell Non-Hodgkin Lymphomas Trial in Boston (Imprime PGG, Rituximab)
Completed
- Relapsed/Refractory Indolent B Cell Non-Hodgkin Lymphomas
- Imprime PGG
- Rituximab
-
Boston, MassachusettsDana Farber Cancer Institute
Sep 20, 2022
Epstein-Barr Virus Infections, Lymphoma, Lymphoproliferative Disorder Trial run by the NCI (Nivolumab)
Recruiting
- Epstein-Barr Virus Infections
- +3 more
- Nivolumab
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jan 24, 2023
Indolent Non-Hodgkin Lymphomas/Chronic Lymphocytic Leukemia Trial in Bergamo (Blinatumomab Expanded T-cells (BET))
Active, not recruiting
- Indolent Non-Hodgkin Lymphomas/Chronic Lymphocytic Leukemia
- Blinatumomab Expanded T-cells (BET)
-
Bergamo, ItalyASST - Papa Giovanni XXIII
Dec 22, 2021
B-cell Non-Hodgkins Lymphoma (B-NHL) Trial (Odronextamab, REGN5837)
Not yet recruiting
- B-cell Non-Hodgkins Lymphoma (B-NHL)
- (no location specified)
Jan 5, 2023
Relapsed Chronic Lymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia, Diffuse Large B Cell Lymphoma Trial in United
Recruiting
- Relapsed Chronic Lymphocytic Leukemia
- +4 more
-
Phoenix, Arizona
- +7 more
Apr 28, 2022
Recurrent Anaplastic Large Cell Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Classic Hodgkin Lymphoma Trial in
Recruiting
- Recurrent Anaplastic Large Cell Lymphoma
- +9 more
- Anti-CD30/CD16A Monoclonal Antibody AFM13
- +4 more
-
Houston, TexasM D Anderson Cancer Center
Aug 9, 2022
Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent DLBCL Trial in Seattle (biological,
Recruiting
- Recurrent B-Cell Non-Hodgkin Lymphoma
- +20 more
- Chimeric Antigen Receptor T-Cell Therapy
- +4 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Jul 11, 2022
B-Cell Non-Hodgkin Lymphoma, Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma Trial in Palo Alto (biological, other,
Active, not recruiting
- B-Cell Non-Hodgkin Lymphoma
- +7 more
- Anti-OX40 Antibody BMS 986178
- +3 more
-
Palo Alto, CaliforniaStanford University, School of Medicine
May 3, 2022
Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma Trial in Atlanta (drug, biological,
Recruiting
- Grade 1 Follicular Lymphoma
- +7 more
- Acalabrutinib
- +3 more
-
Atlanta, GeorgiaEmory University Hospital/Winship Cancer Institute
Dec 7, 2021
Diffuse Large Cell Lymphoma, Non-Hodgkin Lymphoma, Burkitt Lymphoma Trial run by the National Cancer Institute (NCI)
Recruiting
- Diffuse Large Cell Lymphoma
- +4 more
- Vincristine
- +6 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Feb 2, 2023
Triple Negative Breast Cancer, Diffuse Large B Cell Lymphoma, Follicular Lymphoma Trial (ONM-501, Cemiplimab)
Not yet recruiting
- Triple Negative Breast Cancer
- +13 more
- (no location specified)
Aug 29, 2023
Hodgkins Lymphoma, Non Hodgkins Lymphoma Trial in Houston (TAA-specific CTLs)
Recruiting
- Hodgkins Lymphoma
- Non Hodgkins Lymphoma
- TAA-specific CTLs
-
Houston, TexasTexas Children's Hospital
Jul 14, 2022
Non-Hodgkin's Lymphoma Trial in Philadelphia (drug, procedure, genetic)
Completed
- Non-Hodgkin's Lymphoma
- Bendamustine
- +6 more
-
Philadelphia, PennsylvaniaSidney Kimmel Cancer Center at Thomas Jefferson University
Sep 14, 2022
Lymphoma Trial in New York (pralatrexate)
Completed
- Lymphoma
-
New York, New YorkMemorial Sloan-Kettering Cancer Center
Aug 20, 2021
T-cell Non-Hodgkin Lymphoma, Lymphoma, Extranodal NK-T-Cell Trial in Busan, Daegu (Busulfan, Fludarabine)
Recruiting
- T-cell Non-Hodgkin Lymphoma
- Lymphoma, Extranodal NK-T-Cell
-
Busan, Korea, Republic of
- +1 more
Aug 17, 2022
Recurrent DLBCL Germinal Center B-Cell Type, Recurrent Lymphoma, Recurrent Transformed Non-Hodgkin Lymphoma Trial (Belinostat,
Not yet recruiting
- Recurrent Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type
- +5 more
- Belinostat
- +2 more
- (no location specified)
Dec 2, 2022
Aggressive Non-Hodgkin Lymphoma, CD20 Positive, Recurrent B-Cell Non-Hodgkin Lymphoma Trial in Rochester (Laboratory Biomarker
Suspended
- Recurrent Aggressive Non-Hodgkin Lymphoma
- +5 more
- Laboratory Biomarker Analysis
- +2 more
-
Rochester, MinnesotaMayo Clinic in Rochester
Jan 12, 2023
Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma Trial in Morgantown (Busulfan, Fludarabine)
Active, not recruiting
- Hodgkin's Lymphoma
- Non-Hodgkin's Lymphoma
-
Morgantown, West VirginiaWest Virginia University Hospitals Mary Babb Randolph Cancer Cen
Apr 6, 2021